Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

625 results

• ACURASYSAn independent statistical analysis of ACURASYS (NCT00299650), a randomized, quadruple-masked phase 4 trial evaluating systematic early use of neuromuscular blocking agents in patients with ARDS.Phase 4n = 340NCT00299650
• Adhesive Tape Placement on Patients’ Masks in the Emergency Department Increases Compliance of Proper Face Mask Use: Complete Statistical AnalysisIndependent statistical analysis of Adhesive Tape Placement on Patients' Masks in the Emergency Department Increases Compliance of Proper Face Mask Use: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 123NCT04812184
• ADIOSIndependent statistical analysis of Arrhythmia Detection In Obstructive Sleep Apnea (ADIOS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02743520).Phase NAResults postedn = 86NCT02743520
• Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences: Complete Statistical AnalysisIndependent statistical analysis of Advance Care Planning Impact on the Consistency of Older Adults With Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences: primary endpoint results, effect estimate with confidence…Phase NAResults postedn = 124NCT06616909
• ADVANCE-2Independent statistical analysis of the ADVANCE-2 phase 3 trial of apixaban versus enoxaparin for prevention of thrombosis-related events following knee replacement surgery, including endpoint definitions, risk ratios, risk differences, sequential testing, bleeding…Phase 3Results postedn = 3,221NCT00452530
• AERISIndependent statistical analysis of the AERIS randomized trial evaluating a pharmacist-led mHealth serious game intervention for patients with chronic obstructive pulmonary disease, including design, endpoints, methodology, and planned statistical interpretation.Phase NAn = 126NCT07469904
• AFFILIATEIndependent statistical analysis of Effects of Oral Sildenafil on Mortality in Adults With PAH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02060487).Phase 4Results postedn = 385NCT02060487
• AGAVE-201Independent statistical analysis of A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 296NCT04710576
• AHEADIndependent statistical analysis of the randomized phase 3 AHEAD trial comparing budesonide/formoterol Turbuhaler with salmeterol/fluticasone Diskus and terbutaline in asthma, including trial design, endpoints, planned statistical analysis, and interpretation.Phase 3n = 2,100NCT00242775
• AIR-BX2Independent statistical analysis of the AIR-BX2 phase 3 trial of AZLI versus placebo in adults with non-cystic fibrosis bronchiectasis, including its randomized design, QOL-B respiratory-symptom endpoint, MMRM analysis, confidence intervals, p-values, and…Phase 3Results postedn = 274NCT01314716
• AirFLO2Independent statistical analysis of AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04649775).Phase NAResults postedn = 11NCT04649775
• Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath: Complete Statistical AnalysisIndependent statistical analysis of Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness…Phase NAResults postedn = 1,283NCT00442468
• Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01226420).Phase 2Results postedn = 6NCT01226420
• Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 273NCT01045421
• Alpha-1 Carrier Genomics Study: Complete Statistical AnalysisIndependent statistical analysis of Alpha-1 Carrier Genomics Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02810327).Phase NAResults postedn = 117NCT02810327
• Amara View Benchmark Study: Complete Statistical AnalysisIndependent statistical analysis of Amara View Benchmark Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06535932).Phase NAResults postedn = 35NCT06535932
• AmatuximabIndependent statistical analysis of An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 89NCT00738582
• Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 561NCT01399723
• AMPLIFY-201Independent statistical analysis of A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 25NCT04853017
• An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 76NCT03557281
• An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections: primary endpoint results, effect estimate with confidence interval,…Phase 4Results postedn = 71NCT01823289
• An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations: Complete Statistical AnalysisIndependent statistical analysis of An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 2NCT02934698
• An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma: Complete Statistical AnalysisIndependent statistical analysis of An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 51NCT00599027
• An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.: Complete Statistical AnalysisIndependent statistical analysis of An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 45NCT00674817
• An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene: Complete Statistical AnalysisIndependent statistical analysis of An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma…Phase 3Results postedn = 347NCT00932893
• An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 134NCT01362296
• An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026): Complete Statistical AnalysisIndependent statistical analysis of An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026): primary…Phase 3Results postedn = 541NCT02041533
• Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients: Complete Statistical AnalysisIndependent statistical analysis of Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 30NCT01955083
• Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season: Complete Statistical AnalysisIndependent statistical analysis of Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 3Results postedn = 120NCT02381418
• Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01112293).Phase 2Results postedn = 14NCT01112293
• Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma: Complete Statistical AnalysisIndependent statistical analysis of Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003508).Phase 2Results postedn = 8NCT00003508
• Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo: Complete Statistical AnalysisIndependent statistical analysis of Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 22NCT02062710
• Application of 3D Printing Technique in Small Pulmonary Nodule Localization: Complete Statistical AnalysisIndependent statistical analysis of Application of 3D Printing Technique in Small Pulmonary Nodule Localization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02952261).Phase NAResults postedn = 200NCT02952261
• ARCADIANIndependent statistical analysis of Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04648033).Phase 1Results postedn = 21NCT04648033
• ARICAIndependent statistical analysis of AdheRence to Inhaled Corticosteroids in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03769519).Phase NAResults postedn = 29NCT03769519
• ARIES-1An independent statistical analysis of the randomized phase 3 ARIES-1 trial of ambrisentan in pulmonary arterial hypertension, covering trial design, the six-minute walk distance endpoint, planned analysis, statistical interpretation, and limitations.Phase 3n = 186NCT00423748
• ARIES-2An independent statistical analysis and educational interpretation of the phase 3 ARIES-2 trial evaluating ambrisentan in subjects with pulmonary arterial hypertension, including its randomized, double-blind, placebo-controlled design and planned six-minute walk distance…Phase 3n = 186NCT00423202
• Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients: Complete Statistical AnalysisIndependent statistical analysis of Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 67NCT02478580
• ARTEMIS-IPFIndependent statistical analysis of ARTEMIS-IPF, the randomized phase 3 trial of ambrisentan versus placebo in idiopathic pulmonary fibrosis, including its time-to-event endpoint, hazard ratio, secondary analyses, statistical methods, and interpretation.Phase 3Results postedn = 494NCT00768300
• ASPENIndependent statistical analysis of the phase 3 ASPEN trial of brensocatib 10 mg and 25 mg versus placebo in non-cystic fibrosis bronchiectasis, covering negative binomial rate ratios for pulmonary exacerbations, Cox, logistic…Phase 3Results postedn = 1,767NCT04594369
• ASPIREIndependent statistical analysis of Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 43NCT00384813
• Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals’ Pandemic Influenza Vaccine (GSK1562902A) in Adults: Complete Statistical AnalysisIndependent statistical analysis of Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 1,206NCT00449670
• Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 105NCT00323297
• Assessing PA-824 for Tuberculosis (the APT Trial): Complete Statistical AnalysisIndependent statistical analysis of Assessing PA-824 for Tuberculosis (the APT Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02256696).Phase 2Results postedn = 157NCT02256696
• Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI: Complete Statistical AnalysisIndependent statistical analysis of Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03367312).Phase 2Results postedn = 11NCT03367312
• Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin: Complete Statistical AnalysisIndependent statistical analysis of Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 20NCT02552966
• Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD: Complete Statistical AnalysisIndependent statistical analysis of Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 2,021NCT03901534
• Assessment of Cough Reflex in Lung Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Assessment of Cough Reflex in Lung Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00584077).Phase NAResults postedn = 15NCT00584077
• Assessment of Dystussia in Traumatic Brain Injury: Complete Statistical AnalysisIndependent statistical analysis of Assessment of Dystussia in Traumatic Brain Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02240329).Phase EARLY_1Results postedn = 4NCT02240329
• Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO): Complete Statistical AnalysisIndependent statistical analysis of Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 132NCT02720757

← All therapeutic areas